Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Authors:
Open Access
- 25 July 2023
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (14) , 13345-13352
Abstract
Background: Combination of immunotherapy and chemotherapy is recommended for first line treatment of gastric adenocarcinoma (GC) patients with locally advanced unresectable disease or metastatic disease. However, data regarding the concordance rate between PD-L1 combined positive score (CPS) in primary GC and matched regional lymph node metastasis (LNmet) or matched distant metastasis (Dmet) is limited. Methods: Tissue microarray sections from primary resected GC, LNmet and Dmet were immunohistochemically stained with anti-PD-L1 (clone SP263). PD-L1 expression was scored separately in tumour cells and immune cells and compared between matched primary GC, LNmet and/or Dmet. CPS was calculated and results for CPS cut-offs 1 and 5 were compared between matched samples. Results: 275 PD-L1 stained GC were analysed. 189 primary GC had matched LNmet. CPS cut-off 1 concordance rate between primary GC and LNmet was 77%. 23 primary GC had matched Dmet but no matched LNmet, CPS cut-off 1 concordance rate was 70%. 63 primary GC had both matched LNmet and matched Dmet, CPS cut-off 1 concordance rate of 67%. CPS cut-off 5 results were similar. The proportion of PD-L1 positive tumour cells increased from primary GC (26%) to LNmet (42%) and was highest in Dmet (75%). Conclusion: Our study showed up to 33% discordance of PD-L1 CPS between primary GC and LNmet and/or Dmet suggesting that multiple biopsies of primary GC and metastatic sites might need to be tested before considering treatment options. Moreover, this is the first study that seems to suggest that tumour cells acquire PD-L1 expression during disease progression.Keywords
Funding Information
- the Swiss Cancer League (KFS-3700-08-2015)
- Johannes Kepler University Linz
This publication has 25 references indexed in Scilit:
- Preservation of Epstein–Barr virus status and mismatch repair protein status along the metastatic course of gastric cancerHistopathology, 2020
- Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinomaBMC Cancer, 2019
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyGastric Cancer, 2019
- Pathological and Molecular Characteristics of Colorectal Cancer with Brain MetastasesCancers, 2018
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric CancerArchives of Pathology & Laboratory Medicine, 2018
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 ProjectJournal of Thoracic Oncology, 2018
- Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung CancerAnticancer Research, 2017
- Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal MetastasesJournal of Thoracic Oncology, 2017
- Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung CancerClinical Cancer Research, 2016
- PD-L1 is an independent prognostic predictor in gastric cancer of Western patientsOncotarget, 2016